Abstract
Various biological effects of androfurazanol, 17β-hydroxy-17α-methyl-5α-androstano[2, 3-c]furazan, were tested on rats and rabbits as compared wity those of stanozolol, 17β-hydroxy-17α-methyl-5α-androstano[3, 2-c]pyrazole. Androfurazanol was practically devoid of estrogenic effect and was aproximately less active than testosterone propionate in estrous inhibition and gonadotropin inhibition. The gonadotropin-inhibiting effect of the compound is supposed to play an important role in the appearance of estrous inhibition. Furthermore the compound was found to be 0.036 times as active as progesterone in progestational activity. The inhibitions of growth and adrenal weights due to cortisone acetate were antagonized by androfurazanol. The result was comfirmed also with histological examinations of the adrenals. Subcutaneous injection of androfurazanol showed a tendency to decrease the urine volume, and sodium and potassium excretions in doses of 0.1 and 2mg. but the changes were not statistically significant. Intraperitoneal LD50 was 0.494 g./kg. and oral LD50 2.330 g./kg. but all the animals given this compound by subcutaneous injection survived over 2 weeks even in a dose of 4 g./kg.
